B cell biology and dysfunction in SLE

Bulletin of the NYU Hospital for Joint Diseases

Volumn 65, Issue 3, 2007, Pages 182-186

  Anolik, Jennifer H ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b Box 695 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABETIMUS; ALPHA INTERFERON; AUTOANTIBODY; B LYMPHOCYTE RECEPTOR; BELIMUMAB; CYTOKINE; FC RECEPTOR IIB; INTERLEUKIN 1; TUMOR NECROSIS FACTOR;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN PRESENTATION; AUTOIMMUNITY; B LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELL FUNCTION; CELL MATURATION; CELL SURVIVAL; CLINICAL TRIAL; DENDRITIC CELL; GENETIC POLYMORPHISM; HUMAN; HYPERSENSITIVITY REACTION; IMMUNE COMPLEX DISEASE; IMMUNOMODULATION; INNATE IMMUNITY; LYMPHANGIOGENESIS; LYMPHOID TISSUE; NONHUMAN; PATHOGENESIS; POLARIZATION; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; UPREGULATION; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; PATHOLOGY;

ANIMALS; AUTOIMMUNITY; B-LYMPHOCYTES; HUMANS; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC; SIGNAL TRANSDUCTION;

EID: 38449101693     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Kumar KR, Li L, Yan M, et al. Regulation of B cell tolerance by the lupus susceptibility gene Ly108. Science. 2006 Jun;312(5780):1665-9.
2. Bolland S, Ravetch JV. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity. 2000 Aug;13(2):277-85.
3. Fukuyama H, Nimmerjahn F, Ravetch JV. The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat Immunol. 2005 Jan;6(1):99-106.
4. McGaha TL, Sorrentino B, Ravetch JV. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science. 2005 Jan;307(5709):590-3.
5. Floto RA, Clatworthy MR, Heilbronn KR, et al. Loss of function of a lupus-associated FcgammaRIIb polymorphism through exclusion from lipid rafts. Nat Med. 2005 Oct;11(10):1056-8.
6. Mackay M, Stanevsky A, Wang T, et al. Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J Exp Med. 2006 Sep;203(9):2157-64.
7. Liossis SN, Solomou EE, Dimopoulos MA, et al. B-cell kinase lyn deficiency in patients with systemic lupus erythematosus. J Investig Med. 2001 Mar;49(2):157-65.
8. Liossis SN, Kovacs B, Dennis G, et al. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest. 1996 Dec;98(11):2549-57.
9. Mackay F, Woodcock S, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999 Dec;190(11):1697-710.
10. Gross J, Johnston J, Mudri S. TACI and BCMA are receptors for a TNF homologue implicated in B cell autoimmune disease. Nature. 2000 Apr;404(6781):995-9.
11. Stohl W, Metyas S, Tan SM, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations. Arthritis Rheum. 2003 Dec;48(12):3475-86.
12. Lesley R, Xu Y, Kalled SL, et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF.[see comment]. Immunity. 2004 Apr;20(4):441-53.
13. Thien M, Phan TG, Gardant S, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004 Jun;20(6):785-98.
14. Leadbetter EA, Rifkin IR, Hohlbaum AM, et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors.[see comment]. Nature. 2002 Apr;416(6881):603-7.
15. Viglianti GA, Lau CM, Hanley TM, et al. Activation of autoreactive B cells by CpG dsDNA. Immunity. 2003 Dec;19(6):837-47.
16. Boule MW, Broughton C, Mackay F, et al. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med. 2004 Jun;199(12):1631-40.
17. Bave U, Alm GV, Ronnblom L. The combination of apoptotic U937 cells and lupus IgG is a potent IFN-alpha inducer. J Immunol. 2000 Sep; 165(6):3519-26.
18. Bave U, Magnusson M, Eloranta M, et al. Fc gamma RIIa is expressed on natural IFN-alpha producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J Immunol. 2003 Sep;171(6):3296-302.
19. Means TK, Latz E, Hayashi F, et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest. 2005 Feb;115(2):407-17.
20. Pisitkun P, Deane JA, Difilippantonio MJ, et al. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science. 2006 Jun;312(5780):1669-72.
21. Ronnblom L, Alm GV. A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus.[comment]. J Exp Med. 2001 Dec;194(12):F59-63.
22. Arbuckle M, McClain M, Rubertone M, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003 Oct;349(16):1526-33.
23. Chan OT, Madaio MP, Shlomchik MJ. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev. 1999 Jun;169:107-21.
24. Mamula MJ, Fatenejad S, Craft J. B cells process and present lupus autoantigens that initiate autoimmune T cell responses. J Immunol 1994 Feb;152(3):1453-61.
25. Chan OT, Shlomchik MJ. Cutting edge: B cells promote CD8+ T cell activation in MRL-Fas(lpr) mice independently of MHC class I antigen presentation. J Immunol 2000 Feb;164(4):1658-62.
26. Goodnow CC, Cyster JG, Hartley SB, et al. Self-tolerance checkpoints in B lymphocyte development. Adv Immunol. 1995;59:279-368.
27. William J, Euler C, Primarolo N, Shlomchik MJ. B cell tolerance checkpoints that restrict pathways of antigen-driven differentiation. J Immunol. 2006 Feb;176(4):2142-51.
28. Yurasov S, Wardemann H, Hammersen J, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med. 2005 Mar;201(5):703-11.
29. Cappione A 3rd, Anolik JH, Pugh-Bernard A, et al. Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J Clin Invest. 2005 Nov;115(11):3205-16.
30. Pugh-Bernard AE, Silverman GJ, Cappione AJ, et al. Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance. J Clin Invest. 2001 Oct;108(7):1061-70.
31. Tsuiji M, Yurasov S, Velinzon K, et al. A checkpoint for autoreactivity in human IgM+ memory B cell development. J Exp Med. 2006 Feb;203(2):393-400.
32. Wardemann H, Yurasov S, Schaefer A, et al. Predominant autoantibody production by early human B cell precursors. Science. 2003 Sep;301(5638):1374-7.
33. Odendahl M, Jacobi A, Hansen A, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol. 2000 Nov;165(10):5970-9.
34. Cuss A, Avery D, Cannons J, et al. Expansion of functionally immature transitional B cells is associated with human immunodeficient states characterized by impaired humoral immunity. J Immunol. 2006 Feb;176(3):1506-16.
35. Sims GP, Ettinger R, Shirota Y, et al. Identification and characterization of circulating human transitional B cells. Blood. 2005 Jun;105(11):4390-8.
36. Jacobi AM, Odendahl M, Reiter K, et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2003 May;48(5):1332-42.
37. Lin Q, Dong C, Cooper MD. Impairment of T and B cell development by treatment with a type I interferon. J Exp Med. 1998 Jan;187(1):79-87.
38. Cappione A, Pugh-Bernard A, Anolik JH, Sanz I. Lupus IgG VH4.34 Antibodies bind to a 220-kDa glycoform of CD45/B220 on the surface of human B lymphocytes. J Immunol. 2004 Apr;172(7):4298-307.
39. Linton PJ, Harbertson J, Bradley LM. A critical role for B cells in the development of memory CD4 cells. J Immunol. 2000 Nov;165(10):5558-65.
40. Chan OT, Hannum LG, Haberman AM, et al. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med. 1999 May;189(10):1639-48.
41. Martin F, Chan AC. Pathogenic roles of B cells in human autoimmunity: Insights from the clinic. Immunity. 2004 May;20(5):517-27.
42. Shlomchik MJ, Madaio MP, Ni D, et al. The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med. 1994 Oct;180(4):1295-306.
43. Lorenz RG, Chaplin DD, McDonald KG, et al. Isolated lymphoid follicle formation is inducible and dependent upon lymphotoxin-sufficient B lymphocytes, lymphotoxin beta receptor, and TNF receptor I function. J Immunol. 2003 Jun;170(11):5475-82.
44. Ware CF. Network communications: Lymphotoxins, LIGHT, and TNF. Annu Rev Immunol. 2005;23:787-819.
45. Guttikonda R, Chang A, Liu N, et al. Lymphocytes and plasma cells in human lupus nephritis. Arthritis Rheum. 2006, 54:Suppl.
46. Harris D, Haynes L, Sayles P, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol. 2000 Dec;1(6):475-81.
47. Ebert LM, Horn MP, Lang AB, Moser B. B cells alter the phenotype and function of follicular-homing CXCR5+ T cells. Eur J Immunol. 2004 Dec;34(12):3562-71.
48. Vinuesa CG, Cook MC, Angelucci C, et al. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature. 2005 May;435(7041):452-8.
49. Roosnek E, Lanzavecchia A. Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J Exp Med. 1991 Feb;173(2):487-9.
50. Chan O, Shlomchik MJ. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J Immunol. 1998 Jan;160(1):51-9.
51. Leandro M, Edwards J, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002 Oct;46(10):2673-7.
52. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004 Aug;50(8):2580-9.
53. Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: An open-label trial. Arthritis Rheum. 2005 Feb;52(2):501-13.
54. Anolik JH, Barnard J, Owen T, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. In press, 2007.
55. Anolik J, Barnard J, Cappione A, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 2004 Nov;50(11):3580-90.
56. Furie R. Abetimus sodium (riquent) for the prevention of nephritic flares in patients with systemic lupus erythematosus. Rheum Dis Clin North Am. 2006 Feb;32(1):149-56.
57. Kalunian KC, Davis JC, Jr, Merrill JT, et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Dec;46(12):3251-8.
58. Boumpas DT, Furie R, Manzi S, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003 Mar;48(3):719-27.